Soleno Therapeutics (NASDAQ:SLNO) Releases Quarterly Earnings Results

Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings results on Wednesday. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.59 by $0.21, FiscalAI reports. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million.

Here are the key takeaways from Soleno Therapeutics’ conference call:

• Strong financial launch: Q4 net revenue was $91.7M (FY2025 net revenue $190.4M on <9 months of sales), Soleno reached profitability (FY net income $20.9M), generated $48.7M cash from operations in Q4, and finished the year with ~$506M in cash and marketable securities, providing runway for commercialization and expansion.
• Commercial traction: Since launch there were 1,250 patient start forms (~12.5% of the U.S. addressable market), 859 active patients, 630 unique prescribers, and coverage for >180M lives, with the company targeting ~1,000 additional start forms over the next 9–12 months.
• Safety and retention: Real-world safety so far mirrors clinical expectations; launch-to-date discontinuation related to adverse events is ~12% (total discontinuation ~15%), and management expects a long-term discontinuation rate of 15–20%.
• EU regulatory progress: The MAA for DCCR (VYKAT XR) was validated, Day‑120 questions were answered, Day‑180 questions are expected imminently and a mid‑2026 EMA decision is anticipated; the company is preparing commercialization options for a meaningful EU market.
• Pipeline expansion plans: Soleno plans to file an IND for Glycogen Storage Disease Type I in H1 2026 and initiate a clinical program in late 2026, has orphan designations in US/EU, and is evaluating other rare-disease indications leveraging the same mechanism.

Soleno Therapeutics Trading Up 4.7%

SLNO stock traded up $1.85 during midday trading on Wednesday, reaching $41.01. 1,609,942 shares of the company’s stock traded hands, compared to its average volume of 1,357,934. Soleno Therapeutics has a fifty-two week low of $36.67 and a fifty-two week high of $90.32. The company has a market capitalization of $2.20 billion, a P/E ratio of -22.29 and a beta of -3.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The business has a 50-day moving average price of $43.01 and a two-hundred day moving average price of $53.97.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after acquiring an additional 189 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock valued at $45,236,000 after buying an additional 213,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Soleno Therapeutics by 48.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after purchasing an additional 13,211 shares in the last quarter. Creative Planning bought a new stake in Soleno Therapeutics during the second quarter worth approximately $338,000. Finally, Prudential Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter worth $413,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on SLNO. Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. HC Wainwright reissued a “buy” rating and issued a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $114.00 target price (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.62.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.